TCR-Ts

Empowering T cells with tumor-specific T cell receptors (TCR-Ts)

Patient-derived T cells are modified for adoptive T cell therapy with selected and pre-clinically tested T cell receptors (TCR-Ts). TCR-Ts for any selected tumor antigen are generated using Medigene’s TCR-T platform, based on knowledge obtained in more than 30 years of research. Medigene’s growing portfolio of different TCR-Ts have the potential to treat broad patient populations suffering from various types of cancer. 

Medigene’s TCR-T platform offers unique advantages: 

  • Originating from Medigene’s TCR-T platform, TCR-Ts with selected specificities are isolated and characterized and subsequently assessed to potentially treat various types of blood cancers and solid tumors.
  • Isolated TCR-Ts are of natural origin and are chosen to have optimal affinities and hence the TCR-Ts do not need mutational engineering to improve their capacity to find and bind tumor cells.
  • The TCR-T platform can deliver TCR-Ts recognizing a variety of different tumor antigens, representing either common antigens shared by tumors or patient-individual neoantigens.
  • TCR-Ts for both CD4+ and CD8+ T cells can be generated, which recognize peptide fragments presented by different MHC class I and MHC class II alleles, providing greater potential to for effective treatments to larger numbers of patients.

How adoptive T-cell therapy works

Isolation of patient T cells.
Tumor
T cells
Selection of an appropriate TCR-T for a particular indication.
Viral-vector mediated TCR-T transfer
  • The TCR-T is introduced into the patient T cells using a vector system.
  • Modified T cells are expanded to large numbers in 10-15 days.
T cells
TCR-modified T cell
Viral-vector mediated TCR transfer
TCR-modified T cells are reinfused into the patient.
Tumor
TCR-modified T cell
Billions of TCR-modified T cells induce a targeted immune response of combatting large tumor burdens.
TCR-modified T cell

Structure and function of T cell receptors

T cells are distinguished from other lymphocytes by the presence of T cell receptors (TCRs) on the cell surface. TCRs allow T cells to identify cancer targets, e.g. tumor-targeted antigens presented on the surface of the tumor cells. Each T cell receptor is a heterodimeric protein complex composed of one TCR α chain and one TCR β chain. The TCR heterodimers consist of a variable and a constant region. The polypeptide chains are linked together. Each variable region provides a single antigen-binding site. The TCR is associated with a CD3 complex, which combines three transmembrane signaling molecules. TCRs recognize a peptide fragment of a TAA presented by a major histocompatibility complex (MHC) molecule on the target cell. The activation of the T cell to kill the cancer cell starts upon simultaneous binding of a T cell co-receptor complex (CD4+ or CD8+ complex with CD3) to activate the T cell.

Medigene’s TCR-T pipeline

Medigene’s TCR-T pipeline is being built to contain a collection of TCR-Ts that recognize different antigens which are expressed by various types of tumor. Upon completion, Medigene’s TCR-T pipeline will enable individuals of diverse patient populations to be matched for the treatment with TCR-Ts according to their MHC molecules and specificities for antigens expressed by tumor cells. The pipeline is built by natural TCR-Ts with optimal affinities that can be expressed in CD4+ or CD8+ cells, selected by their specificities. Peptide fragments presented by different MHC molecules (both MHC class I and class II allotypes) can be targeted by TCR-Ts to treat different types of tumor.

See Medigene's pipeline

See Medigene's clinical studies

Click on the picture to see a short video of Medigene's TCR technology